Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arch Therapeutics, Inc. (OTC: ARTH).

Full DD Report for ARTH

You must become a subscriber to view this report.


Recent News from (OTC: ARTH)

Arch Therapeutics reports topline results from skin sensitization study of AC5
Arch Therapeutics ( OTCQB:ARTH ) announces topline data for its irritation/sensitization patch test study of AC5 Topical Gel (AC5). The study was designed to address a request by the FDA. More news on: Arch Therapeutics, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 05 2018 08:23
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced topline data for its irritation/sensitization patch test study of AC5™ Topical ...
Source: GlobeNewswire
Date: September, 05 2018 07:50
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018
FRAMINGHAM, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the H.C. Wainwright 20 th Annual Global Investment C...
Source: GlobeNewswire
Date: August, 28 2018 07:50
Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018
FRAMINGHAM, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of AC5™ Topical Gel  (“AC5™”), today announced that new research involving AC5™ will be pre...
Source: GlobeNewswire
Date: August, 16 2018 07:50
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
FRAMINGHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the appointment of Punit Dhillon, former Pr...
Source: GlobeNewswire
Date: July, 20 2018 07:30
Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering
FRAMINGHAM, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“ Arch ” or the “ Company ”), a developer of innovative materials as hemostatic and wound care devices, today announced the pricing of registered direct offering of 9....
Source: GlobeNewswire
Date: June, 29 2018 08:10
Arch Therapeutics Provides Skin Sensitization Study Status Update
FRAMINGHAM, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, provided an update today in which it announced that in the recently initiated skin sensitization study ...
Source: GlobeNewswire
Date: June, 26 2018 07:50
Forty Seven Readies $100 Million U.S. IPO
Quick Take Forty Seven ( FTSV ) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing a new class of immunotherapies which offer a new pathway to people living with cancer, who otherwise may have no other o...
Source: SeekingAlpha
Date: June, 21 2018 13:12
Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study
FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, announced today that it has completed enrollment for its human skin sensitization study and that applica...
Source: GlobeNewswire
Date: June, 15 2018 07:50
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
FRAMINGHAM, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 8 th LD Micro Invitational. The conference is bein...
Source: GlobeNewswire
Date: May, 15 2018 07:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.540.530.540.491248,580
2018-12-120.530.530.550.50990,601
2018-12-110.4380.490.490.433410,600
2018-12-100.440.430.440.41258,177
2018-12-070.4250.4260.4440.422481,909

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-13151,289248,58060.8613Short
2018-12-12463,286990,60146.7682Short
2018-12-11229,791409,60056.1013Short
2018-12-10117,322256,17745.7972Short
2018-12-07145,675481,90930.2287Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARTH.


About Arch Therapeutics, Inc. (OTC: ARTH)

Logo for Arch Therapeutics, Inc. (OTC: ARTH)

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding hemostasis , control leaking sealant and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self assembling barrier technology platform with the goal of making care faster and safer for patients. Arch s development stage product candidates include the AC Topical Gel and the AC Surgical Hemostatic Device.

 

 

 

Current Management

  • Terrence W. Norchi / President, CEO
  • Richard E. Davis / CFO
  • Avtar Dhillon / Chairman, Independent Director
    • As former president and CEO of Inovio Pharmaceuticals, Inc. formerly Inovio Biomedical Corporation , Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over million and secured more than million in licensing deals from global companies including Merck and Wyeth now Pfizer . Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.
  • Terrence W. Norchi /
  • James R. Sulat / Independent Director
    • Mr. Sulat also serves as the Chairman of the Board of Directors for Momenta Pharmaceuticals, Inc., a biotech company focused on the analysis, characterization and design of complex pharmaceutical products. Mr. Sulat has served as a member of the Supervisory Board for Valneva SE or its predecessor company, Intercell AG, both European biotech companies focusing on vaccines, since . Mr. Sulat has served as a member of the Board of Directors for AMAG Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of specialty pharmaceutical products, since . Mr. Sulat has served as a member of the Board of Directors for diaDexus, Inc.since . Previously, Mr. Sulat served as the Chief Executive Officer and Chief Financial Officer for Maxygen, Inc., from to , and a member of the Board of Directors for Maxygen, Inc., from to . Mr. Sulat served as CEO, CFO and a member of the Board for Memory Pharmaceuticals Corp., from to . Mr. Sulat previously served in senior executive roles for R.R. Donnelley amp Sons, Co., Chiron Corporation, Stanford Health Services, Inc., and Esprit de Corp, Inc. Mr. Sulat also previously served as a member of the Board of Directors for Codexis, Inc., Ariat International, Inc., General Surgical Innovations, Inc., and Vans, Inc. Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.

Current Share Structure

  • Market Cap: $51,607,424 - 03/09/2018
  • Authorized: 300,000,000 - 09/30/2016
  • Issue and Outstanding: 154,052,013 - 01/31/2018

 


Recent Filings from (OTC: ARTH)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 06 2018
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: February, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 18 2017
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: November, 15 2017
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: October, 12 2017

 

 


Daily Technical Chart for (OTC: ARTH)

Daily Technical Chart for (OTC: ARTH)


Stay tuned for daily updates and more on (OTC: ARTH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ARTH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARTH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ARTH and does not buy, sell, or trade any shares of ARTH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/